10:52 AM EST - Aeterna Zentaris Inc. : Announced the commencement of the previously announced preclinical program to qualify macimorelin for clinical development as a potential treatment option for amyotrophic lateral sclerosis (ALS; Lou Gehrig's disease). The preclinical development program is part of the recently executed Material Transfer Agreement (MTA) with The University of Queensland. Aeterna Zentaris Inc.
shares T.AEZS are trading down $0.05 at $1.03.